{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-026324","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.038023+00:00","generated_at":"2026-06-05T18:52:59.924473+00:00","sec_items":["1.01","2.02","3.02","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ocular Therapeutix raises $325M in private placement; appoints Pravin Dugel as Executive Chairman","bullets":["Entered securities purchase agreement for 32.4M shares at $7.52/share and pre-funded warrants for 10.8M shares at $7.519/warrant, gross proceeds ~$325M.","Preliminary unaudited cash $195.8M as of Dec 31, 2023; preliminary FY2023 net product revenue ~$57.9M.","Pravin Dugel appointed Executive Chairman, effective Feb 21, 2024; receives $540K base salary, equity awards (1.28M options, 855K RSUs).","CEO Antony Mattessich's employment agreement amended to improve severance benefits; Lead Independent Director Charles Warden appointed.","Proceeds to accelerate AXPAXLI clinical development for wet AMD, including ongoing SOL-1 and planned SOL-2 Phase 3 trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-026324","json":"https://secwatch.observer/filing/0001104659-24-026324.json","markdown":"https://secwatch.observer/filing/0001104659-24-026324.md","text":"https://secwatch.observer/filing/0001104659-24-026324.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924026324/0001104659-24-026324-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924026324/tm246953d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T18:52:59.924473+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fd792dce3cc27bb9f48a57925648154ba490aad9","claim":"OCULAR THERAPEUTIX, INC reported the quarter and year ended December 31, 2023 results: revenue approximately $57.9 million.","evidence_excerpt":"its preliminary, unaudited cash and cash equivalents were approximately $195.8 million as of December 31, 2023, and its preliminary, unaudited net product revenue for the year ended December 31, 2023, was approximately $57.9 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924026324/0001104659-24-026324-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Revenue","value":"approximately $57.9 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"f17622a681","claim":"Pravin U. Dugel, M.D. was appointed as Executive Chairman at OCULAR THERAPEUTIX, INC.","evidence_excerpt":"On February 20, 2024, Pravin U. Dugel, M.D., was appointed as Executive Chairman of the Company and as a Class III director, effective as of February 21, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924026324/0001104659-24-026324-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"},{"claim_id":"876c7eb5925022fc0d8207c597d9a206f20547fd","claim":"OCULAR THERAPEUTIX, INC entered into Securities Purchase Agreement with certain institutional accredited investors valued at approximately $325.0 million (effective 2024-02-21).","evidence_excerpt":"On February 21, 2024, Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 32,413,560 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a price of $7.52 per share and, to certain Investors in lieu of Shares, pre-funded warrants to purchase 10,805,957 shares of the Company’s common stock (the “Pre-Funded Warrants”) at a price of $7.519 per Pre-Funded Warrant (the “Private Placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924026324/0001104659-24-026324-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional accredited investors"},{"label":"Value","value":"approximately $325.0 million"},{"label":"Effective","value":"2024-02-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}